MARKET

TARS

TARS

Tarsus Pharmaceuticals, Inc.
NASDAQ
62.92
-1.42
-2.21%
After Hours: 62.92 0 0.00% 17:27 06/26 EDT
OPEN
64.64
PREV CLOSE
64.34
HIGH
66.50
LOW
60.72
VOLUME
2.03M
TURNOVER
--
52 WEEK HIGH
85.25
52 WEEK LOW
38.51
MARKET CAP
2.71B
P/E (TTM)
-55.5046
1D
5D
1M
3M
1Y
5Y
1D
Noteworthy Friday Option Activity: TARS, LYV, RIOT
NASDAQ · 2d ago
Tarsus Pharma CEO and Chair Bobak R. Azamian disposes of common shares worth $616,864.54
PUBT · 6d ago
Weekly Report: what happened at TARS last week (0615-0619)?
Weekly Report · 6d ago
Tarsus: Not Cheap, But Xdemvy Makes The Valuation Work
Seeking Alpha · 06/19 05:46
Tarsus Pharma Director William J. Link reports $777,809 common share disposal
PUBT · 06/17 20:17
Weekly Report: what happened at TARS last week (0608-0612)?
Weekly Report · 06/15 10:04
Is Conference-Spotlighted XDEMVY Adoption Quietly Reshaping the Long-Term Narrative for Tarsus (TARS)?
Simply Wall St · 06/11 18:24
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Strong Longer Term Returns
Simply Wall St · 06/09 15:27
More
About TARS
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.

Webull offers Tarsus Pharmaceuticals Inc stock information, including NASDAQ: TARS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TARS stock methods without spending real money on the virtual paper trading platform.